Terms: = Thyroid cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
67 results:
1. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies.
Hicks HM; Nassar VL; Lund J; Rose MM; Schweppe RE
Cancer Biol Ther; 2024 Dec; 25(1):2332000. PubMed ID: 38521968
[TBL] [Abstract] [Full Text] [Related]
2. AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and mek1/2 inhibition.
Rose MM; Nassar KW; Sharma V; Schweppe RE
Med Oncol; 2023 Sep; 40(10):299. PubMed ID: 37713162
[TBL] [Abstract] [Full Text] [Related]
3. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in thyroid cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
Hicks HM; Pozdeyev N; Sams SB; Pugazhenthi U; Bales ES; Hofmann MC; McKenna LR; Schweppe RE
Mol Cancer Res; 2023 Sep; 21(9):867-880. PubMed ID: 37219859
[TBL] [Abstract] [Full Text] [Related]
4. Novel Therapeutics for Advanced Differentiated thyroid cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacokinetic Interaction Between the mek1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors.
Arkenau HT; Taylor D; Xu X; Chitnis S; Llacer-Perez C; Moore K; Nidamarthy PK; Ilankumaran P; De Vos-Geelen J
Clin Pharmacol Drug Dev; 2022 May; 11(5):585-596. PubMed ID: 35157784
[TBL] [Abstract] [Full Text] [Related]
6. CCL5 secreted by luminal B breast cancer cells induces polarization of M2 macrophages through activation of MEK/STAT3 signaling pathway via CCR5.
Zhu YY; Zhao YC; Chen C; Xie M
Gene; 2022 Feb; 812():146100. PubMed ID: 34864094
[TBL] [Abstract] [Full Text] [Related]
7. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
Pang R; Yang S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
[TBL] [Abstract] [Full Text] [Related]
8. Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer.
Zhang J; Sun B; Ruan X; Hou X; Zhi J; Meng X; Zheng X; Gao M
Cancer Biol Med; 2021 Feb; 18(1):105-119. PubMed ID: 33628588
[TBL] [Abstract] [Full Text] [Related]
9. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract] [Full Text] [Related]
10. BRAF
Traversi F; Stooss A; Dettmer MS; Charles RP
Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
[No Abstract] [Full Text] [Related]
11. Dabrafenib and Trametinib in Patients With Tumors With
Salama AKS; Li S; Macrae ER; Park JI; Mitchell EP; Zwiebel JA; Chen HX; Gray RJ; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Armstrong DK; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
J Clin Oncol; 2020 Nov; 38(33):3895-3904. PubMed ID: 32758030
[TBL] [Abstract] [Full Text] [Related]
12. Selumetinib: First Approval.
Markham A; Keam SJ
Drugs; 2020 Jun; 80(9):931-937. PubMed ID: 32504375
[TBL] [Abstract] [Full Text] [Related]
13. Magnolin Inhibits Proliferation and Invasion of Breast cancer MDA-MB-231 Cells by Targeting the ERK1/2 Signaling Pathway.
Wang J; Zhang S; Huang K; Shi L; Zhang Q
Chem Pharm Bull (Tokyo); 2020; 68(5):421-427. PubMed ID: 32378540
[TBL] [Abstract] [Full Text] [Related]
14. MicroRNA‑125a‑5p controls the proliferation, apoptosis, migration and PTEN/mek1/2/ERK1/2 signaling pathway in MCF‑7 breast cancer cells.
Liang Z; Pan Q; Zhang Z; Huang C; Yan Z; Zhang Y; Li J
Mol Med Rep; 2019 Nov; 20(5):4507-4514. PubMed ID: 31702027
[TBL] [Abstract] [Full Text] [Related]
15. Characterization of Activating Mutations of the
Borrelli N; Panebianco F; Condello V; Barletta JA; Kaya C; Yip L; Nikiforova MN; Nikiforov YE
Thyroid; 2019 Sep; 29(9):1279-1285. PubMed ID: 31407636
[No Abstract] [Full Text] [Related]
16. Exogenous Hydrogen Sulfide Regulates the Growth of Human thyroid Carcinoma Cells.
Wu D; Li J; Zhang Q; Tian W; Zhong P; Liu Z; Wang H; Wang H; Ji A; Li Y
Oxid Med Cell Longev; 2019; 2019():6927298. PubMed ID: 31223424
[TBL] [Abstract] [Full Text] [Related]
17. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary thyroid cancer.
Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH
J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763
[TBL] [Abstract] [Full Text] [Related]
18. TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling.
Che Y; Li Y; Zheng F; Zou K; Li Z; Chen M; Hu S; Tian C; Yu W; Guo W; Luo M; Deng W; Zou L
Cancer Lett; 2019 Jun; 452():1-13. PubMed ID: 30905820
[TBL] [Abstract] [Full Text] [Related]
19. Mitochondrial metabolism is inhibited by the HIF1α-MYC-PGC-1β axis in BRAF V600E thyroid cancer.
Gao Y; Yang F; Yang XA; Zhang L; Yu H; Cheng X; Xu S; Pan J; Wang K; Li P
FEBS J; 2019 Apr; 286(7):1420-1436. PubMed ID: 30768848
[TBL] [Abstract] [Full Text] [Related]
20. Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases.
Sikorska J; Gaweł D; Domek H; Rudzińska M; Czarnocka B
BMC Cancer; 2019 Jan; 19(1):85. PubMed ID: 30654768
[TBL] [Abstract] [Full Text] [Related]
[Next]
